Skip to content

Study on Effect of Pharmacogenomics-based Point-of-Care Testing on Guiding Precise Antiplatelet and Lipid-lowering Therapies for Acute Ischemic Stroke Patients after rtPA Thrombolysis

Study on Effect of Pharmacogenomics-based Point-of-Care Testing on Guiding Precise Antiplatelet and Lipid-lowering Therapies for Acute Ischemic Stroke Patients after rtPA Thrombolysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090813
Enrollment
Unknown
Registered
2024-10-14
Start date
2025-01-01
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Individualized treatment group:After 24 hours of intravenous thrombolysis, head CT was repeated without bleeding, and clopidogrel rapid test or/and statin gene test were performed, and the drugs were
Conventional treatment group:After 24 hours of intravenous thrombolysis, head CT was repeated without bleeding, and clopidogrel sulfate tablets 75mg once daily orally were administered. Rosuvastatin 1

Sponsors

Dalian Municipal Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-80 years old (2) Patients with acute ischemic stroke or TIA diagnosed by cranial MRI or CT examination in accordance with the criteria of the 2018 China Acute Ischemic Stroke Diagnosis and Treatment Guidelines; and (3) Received intravenous thrombolytic therapy: alteplase dosage was 0.9 mg/kg, with a maximum of 90 mg per patient. 10% of the therapeutic alteplase was injected slowly intravenously over 1 minute, and the remaining 90% was administered homogenously over 60 minutes via an intravenous minipump. (4) Agreed to participate in this study and gave informed consent for case data collection and preservation and follow-up process.

Exclusion criteria

Exclusion criteria: (1) Intracranial hemorrhagic disease as seen on cranial CT; (2) Dementia or psychiatric problems that preclude cooperation with follow-up; (3) Presence of claustrophobia, presence of implanted metallic substances that preclude cranial MR examination; (4) Presence of severe hepatic and renal impairment (5) Failure to sign an informed consent form; (6) Any other condition that the investigator considers unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
New ischemic or hemorrhagic stroke at 180 days;

Secondary

MeasureTime frame
New stroke within 30 days;Vascular events at 90 days;Severe or moderate bleeding within 180 days;Any hemorrhage, death, adverse events and serious adverse events at 180 days follow-up;

Countries

Chnia

Contacts

Public ContactYi Liu

Dalian Municipal Central Hospital

letaliu@bjmu.edu.cn+86 186 2436 1270

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026